Latest Articles
GLP1R Modulates Ferroptosis and Promotes Endometrial Cancer Progression: Insights from AN3CA Cell Study - Medical Dialogues
GLP1R Modulates Ferroptosis and Promotes Endometrial Cancer Progression: Insights from AN3CA Cell Study Medical Dialogues
Published: Feb. 6, 2025, 2:45 p.m.
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay - Medical Device Network
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay Medical Device Network
Published: Feb. 6, 2025, 10 a.m.
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay - Yahoo! Voices
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay Yahoo! Voices
Published: Feb. 6, 2025, 9:54 a.m.
ASCO Reading Room | Is the End of Systemic Chemotherapy Near for Advanced Endometrial Cancer? - Medpage Today
ASCO Reading Room | Is the End of Systemic Chemotherapy Near for Advanced Endometrial Cancer? Medpage Today
Published: Feb. 5, 2025, 7:31 p.m.
Christian Marth on a First-Line Chemotherapy-Free Option for Advanced Endometrial Cancer - Medpage Today
Christian Marth on a First-Line Chemotherapy-Free Option for Advanced Endometrial Cancer Medpage Today
Published: Feb. 5, 2025, 5:54 p.m.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial - Medpage Today
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial Medpage Today
Published: Feb. 5, 2025, 5:54 p.m.
FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer - OncLive
FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer OncLive
Published: Feb. 5, 2025, 5:17 p.m.
A Case of Postoperative Lymphatic Ascites in Endometrial Cancer Spontaneously Resolving After Approximately One Year of Watchful Waiting - Cureus
A Case of Postoperative Lymphatic Ascites in Endometrial Cancer Spontaneously Resolving After Approximately One Year of Watchful Waiting Cureus
Published: Feb. 5, 2025, 1:26 p.m.
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer The Manila Times
Published: Feb. 5, 2025, 1:07 p.m.
Targeting the splicing factor SNRPB inhibits endometrial cancer progression by retaining the POLD1 intron - Nature.com
Targeting the splicing factor SNRPB inhibits endometrial cancer progression by retaining the POLD1 intron Nature.com
Published: Feb. 5, 2025, 11:37 a.m.
Link copied to clipboard!